免疫抑制治疗在骨髓增生异常综合征中的应用:大型国际患者队列的临床结局及其预测因素
该研究纳入来自美国和欧洲15个中心的207例接受免疫抑制治疗(IST)的骨髓增生异常综合征(MDS)患者,评估缓解率、红细胞输血依赖(TI)及总生存(OS)的预测因素。总缓解率(ORR)为48.8%,红细胞输血依赖率为30%,中位OS为47.4个月。获得红细胞输血依赖与低细胞性骨髓(细胞面积<20%)相关,马源抗胸腺细胞球蛋白(ATG)联合环孢素较兔源ATG或不联合环孢素更有效。
要点
- 在207例接受IST的MDS患者中,总缓解率为48.8%,红细胞输血依赖率为30%。
- 获得红细胞输血依赖与低细胞性骨髓(细胞面积<20%)相关。
- 马源ATG联合环孢素较兔源ATG或不联合环孢素更有效。
核心结论
- IST可使近半数经过选择的MDS患者获得客观缓解,低细胞性骨髓患者的红细胞输血依赖率最高。
研究设计与样本
- 研究为国际多中心队列,数据来自美国和欧洲15个中心,共纳入207例接受IST(排除单一激素治疗)的MDS患者。
- 缓解标准依据2006年MDS国际工作组标准,总生存采用Kaplan-Meier法估计,采用逻辑回归模型估计缓解和输血依赖的比值比,采用Cox比例风险模型估计总生存的风险比。
主要发现
- 最常见的IST方案为抗胸腺细胞球蛋白(ATG)联合泼尼松(43%)。
- 总缓解率(ORR)为48.8%,其中完全缓解率为11.2%(95%CI 6.5%-18.4%),红细胞输血依赖率为30%(95%CI 22.3%-39.5%)。
- 中位总生存(OS)为47.4个月(95%CI 37-72.3个月),获得缓解或输血依赖的患者OS更长。
- 获得红细胞输血依赖与低细胞性骨髓(细胞面积<20%)相关;马源ATG联合环孢素较兔源ATG或不联合环孢素更有效。
- 年龄、输血依赖、阵发性睡眠性血红蛋白尿或大颗粒淋巴细胞克隆的存在以及HLA DR15阳性均不能预测IST缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large international cohort of patients with MDS. Data were collected from 15 centers in the United States and Europe. Responses, including red blood cell (RBC) transfusion independence (TI), were assessed based on the 2006 MDS International Working Group criteria, and overall survival (OS) was estimated by Kaplan-Meier methods. Logistic regression models estimated odds for response and TI, and Cox Proportional Hazard models estimated hazards ratios for OS. We identified 207 patients with MDS receiving IST, excluding steroid monotherapy. The most common IST regimen was anti-thymocyte globulin (ATG) plus prednisone (43%). Overall response rate (ORR) was 48.8%, including 11.2% (95% confidence interval [CI], 6.5%-18.4%) who achieved a complete remission and 30% (95% CI, 22.3%-39.5%) who achieved RBC TI. Median OS was 47.4 months (95% CI, 37-72.3 months) and was longer for patients who achieved a response or TI. Achievement of RBC TI was associated with a hypocellular bone marrow (cellularity < 20%); horse ATG plus cyclosporine was more effective than rabbit ATG or ATG without cyclosporine. Age, transfusion dependence, presence of paroxysmal nocturnal hemoglobinuria or large granular lymphocyte clones, and HLA DR15 positivity did not predict response to IST. IST leads to objective responses in nearly half the selected patients with the highest rate of RBC TI achieved in patients with hypocellular bone marrows.
引用
- Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018. PMID: 30037803. doi:10.1182/bloodadvances.2018019414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。